GA01209

Axitinib is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models[3] and has shown partial responses in clinical trials with renal cell carcinoma (RCC)[4] and several other tumour types.

We have successfully synthesized standards of the Axitinib. This will be of interest to pharmaceutical companies and analytical labs.